CMV-specific T-cell immunity in solid organ transplant recipients at low risk of CMV infection. Chronology and applicability in preemptive therapy

Journal of Infection

Volumn 75, Issue 4, 2017, Pages 336-345

  Mena Romo, Juan Damián ^a   Pérez Romero, Pilar ^a   Martín Gandul, Cecilia ^a   Gentil, Miguel Ángel ^b   Suárez Artacho, Gonzalo ^b   Lage, Ernesto ^b   Sánchez, Magdalena ^a   Cordero, Elisa ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

CMV specific T cell immune response; Cytomegalovirus; Immune monitoring; Preemptive therapy; Solid organ transplant patients

Indexed keywords

BASILIXIMAB; CD69 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; DACLIZUMAB; GAMMA INTERFERON; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; ANTIVIRUS AGENT;

ADOLESCENT; ADULT; ARTICLE; CELLULAR IMMUNITY; COHORT ANALYSIS; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SEROLOGY; STAINING; T LYMPHOCYTE; TREATMENT INDICATION; VIRUS REPLICATION; AGED; BLOOD; CD8+ T LYMPHOCYTE; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR; TIME FACTOR; VIROLOGY; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TRANSPLANT RECIPIENTS; VIRAL LOAD;

EID: 85020485011     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2017.05.020     Document Type: Article

References (29)

1. Torre-Cisneros, J., Aguado, J.M., Caston, J.J., Almenar, L., Alonso, A., Cantisan, S., et al. Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev, 2016.
2. Weigand, K., Schnitzler, P., Schmidt, J., Chahoud, F., Gotthardt, D., Schemmer, P., et al. Cytomegalovirus infection after liver transplantation incidence, risks, and benefits of prophylaxis. Transplant Proc 42:7 (2010), 2634–2641.
3. Emery, V.C., Asher, K., Sanjuan Cde, J., Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation. J Clin Virol – Off Publ Pan Am Soc Clin Virol 54:2 (2012), 125–129.
4. Diaz, J., Henao, J., Rodelo, J., Garcia, A., Arbelaez, M., Jaimes, F., Incidence and risk factors for cytomegalovirus disease in a Colombian cohort of kidney transplant recipients. Transplant Proc 46:1 (2014), 160–166.
5. Sester, U., Gartner, B.C., Wilkens, H., Schwaab, B., Wossner, R., Kindermann, I., et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant – Off J Am Soc Transplant Am Soc Transplant Surg 5:6 (2005), 1483–1489.
6. Lilleri, D., Zelini, P., Fornara, C., Comolli, G., Revello, M.G., Gerna, G., Human cytomegalovirus-specific CD4+ and CD8+ T cell responses in primary infection of the immunocompetent and the immunocompromised host. Clin Immunol 131:3 (2009), 395–403.
7. Crough, T., Fazou, C., Weiss, J., Campbell, S., Davenport, M.P., Bell, S.C., et al. Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8(+) T-cell response. J Virol 81:20 (2007), 11538–11542.
8. Gamadia, L.E., Remmerswaal, E.B., Weel, J.F., Bemelman, F., van Lier, R.A., Ten Berge, I.J., Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 101:7 (2003), 2686–2692.
9. Sester, M., Sester, U., Gartner, B., Heine, G., Girndt, M., Mueller-Lantzsch, N., et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71:9 (2001), 1287–1294.
10. Kotton, C.N., Kumar, D., Caliendo, A.M., Asberg, A., Chou, S., Danziger-Isakov, L., et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96:4 (2013), 333–360.
11. Benmarzouk-Hidalgo, O.J., Cisneros, J.M., Cordero, E., Martin-Pena, A., Sanchez, B., Martin-Gandul, C., et al. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment. Transplantation 91:8 (2011), 927–933.
12. Westall, G.P., Mifsud, N.A., Kotsimbos, T., Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant – Off J Am Soc Transplant Am Soc Transplant Surg 8:8 (2008), 1749–1754.
13. Eid, A.J., Brown, R.A., Arthurs, S.K., Lahr, B.D., Eckel-Passow, J.E., Larson, T.S., et al. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection. Transpl Int – Off J Eur Soc Organ Transplant 23:5 (2010), 506–513.
14. Gerna, G., Lilleri, D., Chiesa, A., Zelini, P., Furione, M., Comolli, G., et al. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am J Transplant – Off J Am Soc Transplant Am Soc Transplant Surg 11:11 (2011), 2463–2471.
15. Gerna, G., Lilleri, D., Fornara, C., Comolli, G., Lozza, L., Campana, C., et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant – Off J Am Soc Transplant Am Soc Transplant Surg 6:10 (2006), 2356–2364.
16. Lozza, L., Lilleri, D., Percivalle, E., Fornara, C., Comolli, G., Revello, M.G., et al. Simultaneous quantification of human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. Eur J Immunol 35:6 (2005), 1795–1804.
17. Abate, D., Saldan, A., Fiscon, M., Cofano, S., Paciolla, A., Furian, L., et al. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J Infect Dis 202:4 (2010), 585–594.
18. Bestard, O., Lucia, M., Crespo, E., Van Liempt, B., Palacio, D., Melilli, E., et al. Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation. Am J Transplant – Off J Am Soc Transplant Am Soc Transplant Surg 13:7 (2013), 1793–1805.
19. Lopez-Oliva, M.O., Martinez, V., Buitrago, A., Jimenez, C., Rivas, B., Escuin, F., et al. Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant. Transplantation 97:8 (2014), 839–845.
20. Ljungman, P., Griffiths, P., Paya, C., Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis – Off Publ Infect Dis Soc Am 34:8 (2002), 1094–1097.
21. Egli, A., Humar, A., Kumar, D., State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis – Off Publ Infect Dis Soc Am 55:12 (2012), 1678–1689.
22. Tormo, N., Solano, C., Benet, I., Nieto, J., de la Camara, R., Garcia-Noblejas, A., et al. Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection. J Med Virol 82:7 (2010), 1208–1215.
23. Cantisan, S., Lara, R., Montejo, M., Redel, J., Rodriguez-Benot, A., Gutierrez-Aroca, J., et al. Pretransplant interferon-gamma secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant – Off J Am Soc Transplant Am Soc Transplant Surg 13:3 (2013), 738–745.
24. Bunde, T., Kirchner, A., Hoffmeister, B., Habedank, D., Hetzer, R., Cherepnev, G., et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201:7 (2005), 1031–1036.
25. Blanco-Lobo, P., Cordero, E., Martin-Gandul, C., Gentil, M.A., Suarez-Artacho, G., Sobrino, M., et al. Use of antibodies neutralizing epithelial cell infection to diagnose patients at risk for CMV disease after transplantation. J Infect 72:5 (2016), 597–607.
26. Abate, D., Fiscon, M., Saldan, A., Cofano, S., Mengoli, C., Sgarabotto, D., et al. Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection. J Clin Microbiol 50:6 (2012), 1974–1980.
27. Shabir, S., Kaul, B., Pachnio, A., Banham, G.D., Smith, H., Chand, S., et al. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation. J Am Soc Nephrol 24:10 (2013), 1698–1708.
28. Malek, T.R., The biology of interleukin-2. Annu Rev Immunol 26 (2008), 453–479.
29. Atabani, S.F., Smith, C., Atkinson, C., Aldridge, R.W., Rodriguez-Peralvarez, M., Rolando, N., et al. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant – Off J Am Soc Transplant Am Soc Transplant Surg 12:9 (2012), 2457–2464.